Adverse Drug Reaction
Mostrando 1-12 de 52 artigos, teses e dissertações.
-
1. Association of adverse drug reaction to anti-tuberculosis medication with quality of life in patients in a tertiary referral hospital
Abstract INTRODUCTION: Adverse drug reactions can develop when using anti-tuberculosis medication, and the effects of the drugs can also significantly hinder the treatment of patients. METHODS: A cross-sectional survey was conducted in 73 patients using two standardized questionnaires and the World Health Organization Quality of Life-Bref. RESULTS: All p
Rev. Soc. Bras. Med. Trop.. Publicado em: 20/12/2019
-
2. Suspected adverse drug reactions reported for Brazilian children: cross-sectional study,
RESUMO Objetivo: Analisar relatos espontâneos de suspeitas de Reação Adversa a Medicamento (RAM) em crianças de 0 a 12 anos notificadas pela Agência Nacional de Vigilância Sanitária entre 2008 e 2013. Métodos: Um estudo transversal a partir de notificações de suspeitas de RAM relacionadas a medicamentos e produtos para a saúde em crianças foi r
J. Pediatr. (Rio J.). Publicado em: 25/11/2019
-
3. Reações adversas ao benzonidazol no tratamento da Doença de Chagas: revisão sistemática de ensaios clínicos randomizados e controlados
Resumo Introdução No Brasil, a única droga disponível para o tratamento específico do Trypanosoma cruzi, causador da Doença de Chagas (DC) é o Benzonidazol (BZN), cujas reações adversas podem propiciar a interrupção do tratamento. Objetivo O objetivo desse trabalho é quantificar a proporção de ocorrência de efeitos adversos, descrevê-los e
Cad. saúde colet.. Publicado em: 30/09/2019
-
4. Treatment of actinic keratoses and cancerization field of the face and scalp with 0.015% ingenol mebutate gel in Brazilian individuals: safety, tolerability and patients' perspectives
Abstract: Background: Actinic keratosis (AK) represents a risk of progression to squamous cell carcinoma. Ingenol mebutate gel is a novel therapeutic option for field-directed treatment. Objectives: To evaluate the safety, tolerability and patients' perspectives, related to the therapeutic success of managing AKs on the face and scalp with ingenol mebutate
An. Bras. Dermatol.. Publicado em: 29/07/2019
-
5. Evaluation of the safety and satisfaction of rheumatic patients with accelerated infliximab infusion
Abstract Introduction: Infliximab infusion generally occurs in 2–4 h. Recent studies have suggested the possibility of accelerated infusion (1 h) of this drug. Objective: To evaluate the safety of accelerated infliximab infusion in patients with rheumatic diseases. In addition, patient satisfaction was also assessed. Methods: A prospective, single-cente
Adv. rheumatol.. Publicado em: 29/07/2019
-
6. Results From a 12-Month Open-Label Phase 1/2 Study of Velaglucerase Alfa in Children and Adolescents With Type 3 Gaucher Disease
Abstract Gaucher disease (GD) is an autosomal recessive lipid storage disorder, caused by deficient activity of the lysosomal enzyme b-glucocerebrosidase, resulting in accumulation of glucocerebroside in tissue macrophages. HGT-GCB-068 was an open-label study designed to explore the efficacy and safety of velaglucerase alfa in children and adolescents with t
J. inborn errors metab. screen.. Publicado em: 28/02/2019
-
7. A case series pilot study on the combination of 5-aminolevulinic acid and photodynamic therapy (ALA-PDT) for treatment of vitiligo
Abstract: Background: To study the effective therapeutic concentration, drug application duration, irradiation duration and irradiation dosage of 5-aminolevulinic acid photodynamic therapy (ALA-PDT) for treating vitiligo and observe its clinical efficacy. Objective: To assess the clinical efficacy of ALA-PDT for treating vitiligo. Methods: ALA with differ
An. Bras. Dermatol.. Publicado em: 2018-08
-
8. Increase of 10% in the Rate of Adverse Drug Reactions for Each Drug Administered in Hospitalized Patients
OBJECTIVE: To assess the risk factors, incidence and severity of adverse drug reactions in in-patients. METHODS: This prospective study evaluated 472 patients treated at a teaching hospital in Brazil between 2010 and 2013 by five medical specialties: Internal Medicine, General Surgery, Geriatrics, Neurology, and Clinical Immunology and Allergy. The followi
Clinics. Publicado em: 08/02/2018
-
9. Sweet syndrome-like cutaneous drug reaction
Abstract: Cutaneous drug reactions are adverse reactions to medications that may present with different clinical features, ranging from localized to generalized lesions. In this report we describe a case of an unusual drug reaction, resembling the morphology of Sweet syndrome lesions. The patient had a psychiatric illness and was using thioridazine hydrochlo
An. Bras. Dermatol.. Publicado em: 2017-12
-
10. Necrolisis epidérmica tóxica: un paradigma de enfermedad crítica
ABSTRACT Toxic epidermal necrolysis is an adverse immunological skin reaction secondary in most cases to the administration of a drug. Toxic epidermal necrolysis, Stevens-Johnson syndrome, and multiform exudative erythema are part of the same disease spectrum. The mortality rate from toxic epidermal necrolysis is approximately 30%. The pathophysiology of tox
Rev. bras. ter. intensiva. Publicado em: 2017-12
-
11. Drug reaction with eosinophilia and systemic symptoms (DRESS) and its relation with autoimmunity in a reference center in Mexico
Abstract: BACKGROUND: Drug reaction with eosinophilia and systemic symptoms is a severe adverse drug reaction, with a reported mortality of 10%. Long-term outcomes involve organic failure and autoimmune diseases in some populations. OBJECTIVE: To evaluate the clinical prognosis of patients with drug reaction with eosinophilia and systemic symptoms. METHOD
An. Bras. Dermatol.. Publicado em: 2017-02
-
12. Adverse systemic reaction to benznidazole
Abstract Benznidazole, drug of choice for Chagas disease (CD), has been associated with a high incidence of adverse reactions that can become serious, necessitating discontinuation of the drug. We describe the case of a Bolivian patient living in Spain for 9 years, who, following treatment with benznidazole for CD in indeterminate chronic phase, presented wi
Rev. Soc. Bras. Med. Trop.. Publicado em: 2017-02